Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Cipla Q3 Results FY25–26: Net Profit ₹674 Cr, Down 57.2% YoY, Revenue ₹7,074 Crore

Synopsis:


Cipla reported consolidated revenue from operations of ₹7,074.48 crore in Q3 FY25–26, broadly flat YoY. Net profit stood at ₹674.25 crore, reflecting a decline compared to the year-ago quarter, impacted by exceptional items, as per its exchange filing.

Cipla announced its unaudited consolidated financial results on 23 January 2026 for the quarter ended December 31, 2025 (Q3 FY25–26). The company reported stable revenue performance, while profitability declined on a year-on-year basis due to lower operating profit and an exceptional loss during the quarter.

On a consolidated basis, revenue from operations stood at ₹7,074.48 crore, while net profit for the quarter came in at ₹674.25 crore.

Cipla Q3 Results FY25–26 Date & Announcement

Cipla declared its Q3 FY25–26 financial results on 23 January 2026, covering the consolidated performance for the quarter ended December 31, 2025, as disclosed through its stock exchange filing.

Cipla Ltd

Trade

1315-55.40 (-4.04 %)

Updated - 23 January 2026
1385.90day high
DAY HIGH
1303.00day low
DAY LOW
6590032
VOLUME (BSE)

Cipla Q3 Results FY25–26 – Key Financial Highlights (Consolidated)

All figures in ₹ crore | Consolidated | Unaudited

Particulars

Q3 FY25–26

Q2 FY25–26

Q3 FY24–25

YoY %

QoQ %

Revenue from the Sale of Products

6,962.97

7,447.42

6,961.60

0.0%

(6.5%)

Other Operating Revenue

111.51

142.02

111.37

0.1%

(21.5%)

Total Revenue from Operations

7,074.48

7,589.44

7,072.97

0.0%

(6.8%)

Other Income

206.34

268.95

221.61

(6.9%)

(23.3%)

Total Income

7,280.82

7,858.39

7,294.58

(0.2%)

(7.3%)

Total Expenses

6,111.80

6,004.86

5,378.49

13.6%

1.8%

Profit Before Exceptional Items & Tax

1,169.02

1,853.53

1,916.09

(39.0%)

(36.9%)

Exceptional Item (Loss)

(275.91)

Profit Before Tax (PBT)

893.11

1,853.53

1,916.09

(53.4%)

(51.8%)

Tax Expense (Net)

218.55

500.46

332.37

(34.2%)

(56.3%)

Net Profit (PAT)

674.25

1,353.37

1,574.59

(57.2%)

(50.2%)

EPS – Basic (₹)

8.37

16.73

19.45

(57.0%)

(50.0%)

EPS – Diluted (₹)

8.36

16.72

19.43

(57.0%)

(50.0%)

Cipla Q3 FY25–26 vs Q2 FY25–26 – Comparison (Consolidated)

All figures in ₹ crore | Consolidated | Unaudited

Particulars

Q3 FY25–26

Q2 FY25–26

QoQ Change

Total Revenue from Operations

7,074.48

7,589.44

(6.8%)

Other Income

206.34

268.95

(23.3%)

Total Income

7,280.82

7,858.39

(7.3%)

Total Expenses

6,111.80

6,004.86

1.8%

Profit Before Tax (PBT)

893.11

1,853.53

(51.8%)

Tax Expense (Net)

218.55

500.46

(56.3%)

Net Profit (PAT)

674.25

1,353.37

(50.2%)

EPS – Basic (₹)

8.37

16.73

(50.0%)

EPS – Diluted (₹)

8.36

16.72

(50.0%)

On a quarter-on-quarter basis, Cipla reported a decline in profitability as revenue moderated sequentially while costs remained elevated, resulting in lower earnings during the quarter.

Cipla Q3 Business Segment Performance (Consolidated)

Figures are consolidated, unaudited, and represent Q3 FY25–26 only.

Segment Revenue (₹ Cr)

Segment

Q3 FY25–26 Revenue

Q2 FY25–26 Revenue

Q3 FY24–25 Revenue

Pharmaceuticals

6,746.40

7,291.43

6,777.84

New Ventures

381.48

350.68

341.30

Total Segment Revenue

7,127.88

7,642.11

7,119.14

Less: Inter-segment Revenue

(53.40)

(52.67)

(46.17)

Total Revenue from Operations

7,074.48

7,589.44

7,072.97

Segment Result / PBT (₹ Cr)

Segment

Q3 FY25–26 Segment Result

Q2 FY25–26 Segment Result

Q3 FY24–25 Segment Result

Pharmaceuticals

1,122.26

1,825.49

1,888.86

New Ventures

60.79

41.22

41.87

Total Segment Result

1,183.05

1,866.71

1,930.73

Less: Finance Costs

14.03

13.18

14.64

Profit Before Exceptional Items & Tax

1,169.02

1,853.53

1,916.09

Less: Exceptional Item (Loss)

275.91

Profit Before Tax (PBT)

893.11

1,853.53

1,916.09

Pharmaceuticals remained the largest contributor to consolidated revenue and profitability during the quarter, while New Ventures contributed a smaller share of revenue and profit.

Market Reaction After Cipla Q3 Results FY25–26

Cipla released its quarterly results during market hours. As of 2 PM IST on 23 January 2026, Cipla’s share price is trading at ₹1311.55 on the NSE, down by 4.37%.

Conclusion – What Cipla Q3 Results Indicate

Cipla’s Q3 FY25–26 results indicate declining operating revenue but a decline in net profit on both a year-on-year and quarter-on-quarter basis. The performance reflects pressure on profitability during the quarter, along with the impact of an exceptional loss.

For more quarterly result updates, visit Bajaj Broking’s Quarterly Results Calendar.

Share this article: 

Frequently Asked Questions

No result found

search icon
Published Date : 23 Jan 2026

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,900+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|